Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Laufer

Showing results (61-70 of 189) with videos related to

Pageof 19
Sort By:
Journal of Pharmaceutical and Biomedical Analysis|February 15, 2011
A direct ELISA assay for quantitative determination of the inhibitory potency of small molecules inhibitors for JNK3Márcia Goettert, Sabine Luik, Ralph Graeser, et al.
Expert Opinion on Therapeutic Patents|May 21, 2015
c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014)Matthias Gehringer, Felix Muth, Pierre Koch, et al.
Life Sciences|July 4, 1983
Cycloamylose complexation of adamantane derivativesR I Gelb, L M Schwartz, D A Laufer
Journal of Medicinal Chemistry|October 4, 2002
Imidazole inhibitors of cytokine release: probing substituents in the 2 positionStefan A Laufer, Hans-Günther Striegel, Gerd K Wagner
Angewandte Chemie (International Ed. in English)|October 11, 2017
The Cysteinome of Protein Kinases as a Target in Drug DevelopmentApirat Chaikuad, Pierre Koch, Stefan A Laufer, et al.
Mutation Research. Reviews in Mutation Research|November 6, 2023
Applications of advanced technologies for detecting genomic structural variationVincent A Laufer, Thomas W Glover, Thomas E Wilson
Journal of Clinical Psychology|October 1, 1981
Purpose in life and occupational interest in a gerontological sheltered workshopW S Laufer, E A Laufer, L S Laufer
Journal of Medicinal Chemistry|June 10, 1994
(6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenaseS A Laufer, J Augustin, G Dannhardt, et al.
Clinical Orthopaedics and Related Research|May 1, 1985
Aggressive osteoblastoma. A case report and review of the literatureS Kenan, Y Floman, G C Robin, et al.
Expert Opinion on Therapeutic Patents|April 2, 2020
An updated patent review of p38 MAP kinase inhibitors (2014-2019)Vanessa Haller, Philipp Nahidino, Michael Forster, et al.
Pageof 19

Showing results (61-70 of 189) with videos related to

Sort By:
Pageof 19
Journal of Pharmaceutical and Biomedical Analysis|February 15, 2011
A direct ELISA assay for quantitative determination of the inhibitory potency of small molecules inhibitors for JNK3Márcia Goettert, Sabine Luik, Ralph Graeser, et al.
Expert Opinion on Therapeutic Patents|May 21, 2015
c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014)Matthias Gehringer, Felix Muth, Pierre Koch, et al.
Life Sciences|July 4, 1983
Cycloamylose complexation of adamantane derivativesR I Gelb, L M Schwartz, D A Laufer
Journal of Medicinal Chemistry|October 4, 2002
Imidazole inhibitors of cytokine release: probing substituents in the 2 positionStefan A Laufer, Hans-Günther Striegel, Gerd K Wagner
Angewandte Chemie (International Ed. in English)|October 11, 2017
The Cysteinome of Protein Kinases as a Target in Drug DevelopmentApirat Chaikuad, Pierre Koch, Stefan A Laufer, et al.
Mutation Research. Reviews in Mutation Research|November 6, 2023
Applications of advanced technologies for detecting genomic structural variationVincent A Laufer, Thomas W Glover, Thomas E Wilson
Journal of Clinical Psychology|October 1, 1981
Purpose in life and occupational interest in a gerontological sheltered workshopW S Laufer, E A Laufer, L S Laufer
Journal of Medicinal Chemistry|June 10, 1994
(6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenaseS A Laufer, J Augustin, G Dannhardt, et al.
Clinical Orthopaedics and Related Research|May 1, 1985
Aggressive osteoblastoma. A case report and review of the literatureS Kenan, Y Floman, G C Robin, et al.
Expert Opinion on Therapeutic Patents|April 2, 2020
An updated patent review of p38 MAP kinase inhibitors (2014-2019)Vanessa Haller, Philipp Nahidino, Michael Forster, et al.
Pageof 19